We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sesen Bio Inc | NASDAQ:SESN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.6288 | 0.6005 | 0.629 | 0 | 01:00:00 |
From May 2021 to May 2024
By Josh Beckerman
Sesen Bio Inc. shares were recently up 33% to $1.34 after it provided updates on U.S. and Europe drug approval steps in securities filings.
Sesen said Tuesday that the Food & Drug Administration granted its request for a Type A meeting to discuss the chemistry, manufacturing and controls issues raised in the FDA's complete response letter for Vicineum.
On Wednesday, Sesen said the European Medicines Agency issued a withdrawal assessment report for the company's Vysyneum application.
"Due to the high concordance between FDA and European Commission approvals, the company believes that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained," the company said.
Sesen shares fell sharply in August when the FDA issued a CRL on its application for Vicineum for treatment of BCG-unresponsive non-muscle invasive bladder cancer.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 20, 2021 15:57 ET (19:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sesen Bio Chart |
1 Month Sesen Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
